Senores Pharmaceuticals Limited (SPL), through its wholly-owned US subsidiary, Senores Pharmaceuticals, Inc. (SPI), has entered into an agreement to acquire the USFDA-approved Abbreviated New Drug Application (ANDA) for Enalapril Maleate Tablets in four strengths: 2.5 mg, 5 mg, 10 mg, and 20 mg. The ANDA is being acquired from Wockhardt Limited.
Enalapril Maleate is a generic pharmaceutical product indicated for the treatment of hypertension, heart failure, and asymptomatic left ventricular dysfunction. It is a widely prescribed medication in cardiovascular therapy.
According to IQVIA, the U.S. market size for Enalapril Tablets was approximately USD 28.60 million as of MAT December 2024. Data from Symphony, a specialty data aggregator, places the market size at around USD 109.24 million as of MAT March 2025. The variation in estimates is attributed to differing data methodologies and sources.
The acquisition by SPL will be financed using proceeds from the company’s recent Initial Public Offering (IPO), aligning with the intended use of funds outlined in the Red Herring Prospectus filed during the IPO process.
About Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited is a research-focused pharmaceutical company engaged in the development and manufacturing of a diverse portfolio of pharmaceutical products. The company, along with its subsidiaries, serves regulated and emerging markets including the United States and Canada, with a focus on various therapeutic segments and dosage forms.
